DAIICHI SANKYO CO LTD Share Price Today: Live Updates & Key Insights

DAIICHI SANKYO CO LTD share price today is $null, up null%. The stock opened at $null against the previous close of $null, with an intraday high of $null and low of $null.

DAIICHI SANKYO CO LTD Share Price Chart

DAIICHI SANKYO CO LTD

us-stock
To Invest in {{usstockname}}
us-stock

DAIICHI SANKYO CO LTD Share Price Performance

$null null(null%) null at 23 Mar 2026 12:46 PM Drug Manufacturers - General
Lowest Today 0.00
Highest Today 0.00
Today’s Open 0.00
Prev. Close 0.00
52 Week High 27.50
52 Week Low 17.44
Day’s Range: Low null High null
52-Week Range: Low 17.44 High 27.50
1 day return -
1 Week return -
1 month return -
3 month return -
6 month return -
1 year return -
3 year return -
5 year return -
10 year return -

DAIICHI SANKYO CO LTD Institutional Holdings

DAIICHI SANKYO CO LTD Market Status

DAIICHI SANKYO CO LTD Fundamentals

Market Cap 32995.80 M

PB Ratio 3.0828

PE Ratio 19.1383

Enterprise Value 30929.33 M

Total Assets 3456119.00 M

Volume null

DAIICHI SANKYO CO LTD Company Financials

Annual Revenue FY25:1886256000000 1886256.0M, FY24:1601688000000 1601688.0M, FY23:1278478000000 1278478.0M, FY22:1044892000000 1044892.0M, FY21:962516000000 962516.0M

Annual Profit FY25:1470458000000 1470458.0M, FY24:1186366000000 1186366.0M, FY23:914953000000 914953.0M, FY22:691564000000 691564.0M, FY21:624227000000 624227.0M

Annual Net worth FY25:295756000000 295756.0M, FY24:200731000000 200731.0M, FY23:109188000000 109188.0M, FY22:66972000000 66972.0M, FY21:75958000000 75958.0M

Quarterly Revenue Q4/2025:568181298000 568181.3M, Q3/2025:509486000000 509486.0M, Q2/2025:474597000000 474597.0M, Q1/2025:518689000000 518689.0M, Q2/2024:436175000000 436175.0M

Quarterly Profit Q4/2025:447767048000 447767.0M, Q3/2025:350786000000 350786.0M, Q2/2025:382251000000 382251.0M, Q1/2025:424351000000 424351.0M, Q2/2024:341126000000 341126.0M

Quarterly Net worth Q4/2025:88195938000 88195.9M, Q3/2025:46104000000 46104.0M, Q2/2025:85500000000 85500.0M, Q1/2025:87153000000 87153.0M, Q2/2024:85383000000 85383.0M

About DAIICHI SANKYO CO LTD & investment objective

Company Information Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation for the treatment of symptomatic TGCT; Vanflyta, a FLT3 inhibitor to treat adult patients with acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and DATROWAY to treat adult patients with breast cancer and NSCLC. It also provides Liziana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo, an oral treatment that lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia and Tenelia for the treatment of type 2 diabetes mellitus; Emgalty and Reyvow to treat migraine attacks; Pralia for the treatment of osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark to treat bone complications and GCTB; Tarlige for the treatment of neuropathic pain; Venofer to treat iron deficiency anemia; and Vimpat, an anti-seizure medication. Further, it provides vaccines for the treatment of COVID-19, influenza infections, adsorbed cell culture-derived influenza (H5N1) influenza infections, measles/rubella infections, and mumps infections. The company has a strategic collaboration with Lunit Inc. for the development of biomarker discovery and optimize translational research. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Chuo, Japan.

Organisation Drug Manufacturers - General

Employees 19765

Industry Drug Manufacturers - General

CEO Mr. Hiroyuki Okuzawa

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

DAIICHI SANKYO CO LTD FAQs

What is the share price of DAIICHI SANKYO CO LTD today?

The current share price of DAIICHI SANKYO CO LTD is $null.

Can I buy DAIICHI SANKYO CO LTD shares in India?

Yes, Indian investors can buy DAIICHI SANKYO CO LTD shares by opening an international trading and demat account with Motilal Oswal.

How to buy DAIICHI SANKYO CO LTD shares in India?

You can easily invest in DAIICHI SANKYO CO LTD shares from India by:

Can I buy fractional shares of DAIICHI SANKYO CO LTD?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of DAIICHI SANKYO CO LTD?

DAIICHI SANKYO CO LTD has a market cap of $32995.80 M.

In which sector does DAIICHI SANKYO CO LTD belong?

DAIICHI SANKYO CO LTD operates in the Drug Manufacturers - General sector.

What documents are required to invest in DAIICHI SANKYO CO LTD stocks?

To invest, you typically need:

What is the PE and PB ratio of DAIICHI SANKYO CO LTD?

The PE ratio of DAIICHI SANKYO CO LTD is 19.14 and the PB ratio is 3.08.